The industry is awaiting the progress on whether 'Camzyos,' the first novel drug for obstructive hypertrophic cardiomyopathy (oHCM), will receive an insurance reimbursement listing.

According to industry sources, BMS Korea’s novel drug Camzyos (mavacamten) has cleared the review by the Economic Evaluation Committee of Health Insurance Review and Assessment Service (HIRA). It is now being scheduled for the Drug Reimbursement Evaluation Committee (DREC) review. It is expected that Camzyos will be considered for the DREC review in June.

Because Camzyos is the first treatment option for the particular disease to receive a review, it is to be watched what outcome will be yielded from the f